Eplerenone reduces urinary Albumin creatinine ratio in diabetics at high risk of CVD: Study

Published On 2021-10-18 03:30 GMT   |   Update On 2021-10-18 03:30 GMT

Eplerenone improves Albumin Excretion in type 2 diabetes (T2D) With Acceptable Safety, suggests a study published in the Diabetes and Metabolism.

As mineralocorticoid receptor antagonists (MRAs) may possess renoprotective effects in type 2 diabetes (T2D), it was decided to investigate the impact of high-dose MRA on prespecified secondary endpoints—namely, change in urinary albumin–creatinine ratio (UACR) and 24-h ambulatory blood pressure—in the MIRAD trial.


This was a double-blind clinical trial in which type 2 diabetes (T2D) patients at high risk of or with established cardiovascular disease (CVD) were randomized to either high-dose (100–200 mg) eplerenone or a dose-matched placebo as an add-on to background antihypertensive treatment for 26 weeks. Safety was evaluated by the incidence of hyperkalemia and kidney-related adverse events.


The results of the study are as follows:

  • A total of 140 patients were enrolled (70 in each group).
  • Baseline urinary albumin–creatinine ratio (UACR) was 17 mg/g; this decreased by 34% in the eplerenone group compared with the placebo group at week 26.
  • There was no significant decrease in 24-h systolic blood pressure (SBP) due to treatment.
  • However, the observed change in 24-h SBP correlated with the relative change in urinary albumin–creatinine ratio (UACR) in the eplerenone group.
  • Mean baseline (± SD) estimated glomerular filtration rate (eGFR) was 85 (± 18.6) mL/min/1.73 m2, and 12 (± 9%) had an eGFR of 41–59 mL/min/1.73 m2.
  • No significant differences in the incidence of mild hyperkalaemia and no severe hyperkalaemia were observed.

Thus, the researchers concluded that the addition of high-dose eplerenone to type 2 diabetes (T2D) patients at high risk of cardiovascular disease can markedly reduce UACR with an acceptable safety profile.


A study titled, "Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial" by Niels H.Brandt-Jacobsen published in the Diabetes and Metabolism.


Article Source : Diabetes & Metabolism

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News